期刊文献+

盐酸坦索洛辛治疗高危高龄前列腺增生症的疗效观察 被引量:1

下载PDF
导出
摘要 目的观察盐酸坦索洛辛治疗高危高龄前列腺增生症的临床疗效。方法 160例前列腺增生症患者应用坦索洛辛口服治疗。结果治疗前后患者的IPSS、QOL评分及PVR、Qmax比较差异均有统计学意义(P<0.01)。治疗前后患者血压、血糖、血脂、肝功能无显著性变化。无一例体位性低血压发生。8周后有20例接受经尿道前列腺电切术(TURP),3例因尿潴留选择耻骨上膀胱穿刺造瘘。结论盐酸坦索洛辛治疗高危、高龄前列腺增生症具有安全、方便、效果明显、不良反应少等优点,可作为有TURP禁忌患者有效的短时治疗性药物,为择期TURP提供时间。
出处 《临床合理用药杂志》 2011年第11X期60-61,共2页 Chinese Journal of Clinical Rational Drug Use
  • 相关文献

参考文献7

  • 1Stavros Gravas,Matthias Oelke.Current status of 5-reductase inhibitors in the management of lower urinary tract symptoms and BPH[J].World J Urol,2010,28(4):9-15.
  • 2Agus Rizal A.H.Hamid,Rainy Umbas,Chaidir A.Mochtar.Recent Role of Inflammation in Prostate Diseases:Chemoprevention Development Opportunity[J].Acta Med Indones-Indones,2011,43(1):59-65.
  • 3曾凡雄,李克庆,杨冰.盐酸坦索罗辛治疗不同体积BPH的疗效观察[J].临床泌尿外科杂志,2008,23(11):880-880. 被引量:4
  • 4许传亮,张振声,孙颖浩.良性前列腺增生症的药物治疗及其长期用药[J].中华老年医学杂志,2007,26(8):639-640. 被引量:15
  • 5许传亮,张振声,孙颖浩.良性前列腺增生症患者长期药物治疗一例[J].中华老年医学杂志,2007,26(9):707-708. 被引量:2
  • 6Clark RV,Hermann DJ,Cunningham GR,et al.Markedsuppression of dihydrotestosterone in men with benign prostatic hyperplasia by dutasteride,a dual 5alpha-reductase inhibitor[J].J Clin Endocrinol Metab,2010,89(6):2179-2184.
  • 7Roehrborn CG,Boyle P,Nickel JC,et al.A Study Investigators cacy and safety of Ya dual inhibitor of 5-alpha-reductase types 1 and 2 (dutasteride) in men with benign prostatic hyperplasia[J].Urology,2009,60(4):434-441.

二级参考文献7

  • 1那彦群,汪迪,金杰,郭应禄,薛兆英,顾方六.选择性α_(1a)受体阻断剂治疗前列腺增生症[J].中华泌尿外科杂志,1996,17(6):327-329. 被引量:22
  • 2Roehrborn CG, McConnell JD, Liber M, et al. Serum prostate specific antigen concentration is a powerful predictor of acute urinary retention and need for surgery in men with clinical benign prostatic hyperplasia. PLESS study group. Urology, 1999, 53: 473-480.
  • 3Jacobsen SJ, Jacobson DJ, Girman, et al. Natural history of prostatism: risk factors for acute urinary retention. J Urol, 1997, 158:481-487.
  • 4Roehrborn CG, Boyle P, Bergner D, et al. Serum prostate-specific antigen and prostate volume predict long-term changes in symptoms and flow-rate : results of a four years, randomized trial comparing finasteride versus placebo. PLESS Study Group. Urol, 1999, 54: 662.
  • 5Nickel JC, Fradet Y, Boake RC, et al. Efficacy and safety of finasteride therapy for benign prostatic hyperplasia: results of a 2-year randomized controlled trial (the PROSPECT Study). Can Med Assoc J, 1996, 155: 1251-1259.
  • 6Djavan B, Marberger M. Meta analysis on the efficacy and tolerability of alphal-adrenoceptor antagonists in patients with lower urinary traet symptoms suggestive of benign prostatic obstruction. Eur Urol, 1999, 36:1-13.
  • 7McConnell JD, Roehrborn CG, Baustita OM, et al. The long-term effect of doxazosin, finasteride, and combination therapy on the clinical progression of benign prostatic hyperplasia. N Engl J Med , 2003,349 : 2387-2398

共引文献18

同被引文献21

引证文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部